|
|
||||||||
Centre for Pulmonary Vascular Diseases UPRES EA 2705, Dept of Respiratory and Intensive Care Medicine, South Paris Cytokine Institute, Antoine Béclère Hospital, Assistance Publique-Hôpitaux de Paris, South Paris University, Clamart, France
CORRESPONDENCE: M. Humbert, Dept of Respiratory and Intensive Care Medicine, Antoine Béclère Hospital, 157 rue de la Porte de Trivaux, 92140 Clamart, France. Fax: 33 146303824. E-mail: humbert@ipsc.u-psud.fr
Keywords: chemokines, connective tissue disease, endothelial cells, inflammatory infiltrate, pulmonary arterial hypertension, monocrotaline
Received: April 7, 2003
Accepted April 16, 2003
This group has been supported in part by grants from Legs Poix, Université Paris-Sud, Association Française contre les Myopathies and Institut National de la Santé et de la Recherche Médicale.
Abstract
Inflammatory mechanisms appear to play a significant role in some types of pulmonary hypertension (PH), including monocrotaline-induced PH in rats and pulmonary arterial hypertension of various origins in humans, such as connective tissue diseases (scleroderma, systemic lupus erythematosus, mixed connective disease), human immunodeficiency virus infection, or plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal (M) protein and skin changes (POEMS) syndrome.
Interestingly, some patients with severe pulmonary arterial hypertension associated with systemic lupus erythematosus have experienced significant improvements with immunosuppressive therapy, emphasising the relevance of inflammation in a subset of patients presenting with PH. Patients with primary PH (PPH) also have some immunological disturbances, suggesting a possible role for inflammation in the pathophysiology of this disease. A subset of PPH patients have been shown to have circulating autoantibodies, including antinuclear antibodies, as well as elevated circulating levels of the pro-infammatory cytokines, interleukins -1 and -6. Lung histology has also revealed inflammatory infiltrates in the range of plexiform lesions in patients displaying severe PPH, as well as an increased expression of the chemokines regulated upon activation, normal T-cell expressed and secreted (RANTES) and fractalkine.
Further analysis of the role of inflammatory mechanisms is necessary to understand whether this component of the disease is relevant to its pathophysiology.
This article has been cited by other articles:
![]() |
D. Montani, L. C. Price, P. Dorfmuller, L. Achouh, X. Jais, A. Yaici, O. Sitbon, D. Musset, G. Simonneau, and M. Humbert Pulmonary veno-occlusive disease Eur. Respir. J., January 1, 2009; 33(1): 189 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. West, J. Harral, K. Lane, Y. Deng, B. Ickes, D. Crona, S. Albu, D. Stewart, and K. Fagan Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L744 - L755. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aytekin, S. A. A. Comhair, C. de la Motte, S. K. Bandyopadhyay, C. F. Farver, V. C. Hascall, S. C. Erzurum, and R. A. Dweik High levels of hyaluronan in idiopathic pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L789 - L799. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Butrous, H. A. Ghofrani, and F. Grimminger Pulmonary Vascular Disease in the Developing World Circulation, October 21, 2008; 118(17): 1758 - 1766. [Full Text] [PDF] |
||||
![]() |
E. D. Michelakis, M. R. Wilkins, and M. Rabinovitch Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension Circulation, September 30, 2008; 118(14): 1486 - 1495. [Full Text] [PDF] |
||||
![]() |
T. Henriques-Coelho, S. M. Oliveira, R. S. Moura, R. Roncon-Albuquerque Jr., A. L. Neves, M. Santos, C. Nogueira-Silva, F. La Fuente Carvalho, A. Brandao-Nogueira, J. Correia-Pinto, et al. Thymulin Inhibits Monocrotaline-Induced Pulmonary Hypertension Modulating Interleukin-6 Expression and Suppressing p38 Pathway Endocrinology, September 1, 2008; 149(9): 4367 - 4373. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice FASEB J, June 1, 2008; 22(6): 1849 - 1860. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huang, P. M. Kaminski, J. G. Edwards, A. Yeh, M. S. Wolin, W. H. Frishman, M. H. Gewitz, and R. Mathew Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1250 - L1259. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Humbert Update in Pulmonary Arterial Hypertension 2007 Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 574 - 579. [Full Text] [PDF] |
||||
![]() |
B. Bakouboula, O. Morel, A. Faure, F. Zobairi, L. Jesel, A. Trinh, M. Zupan, M. Canuet, L. Grunebaum, A. Brunette, et al. Procoagulant Membrane Microparticles Correlate with the Severity of Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 536 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Asosingh, M. A. Aldred, A. Vasanji, J. Drazba, J. Sharp, C. Farver, S. A.A. Comhair, W. Xu, L. Licina, L. Huang, et al. Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension Am. J. Pathol., March 1, 2008; 172(3): 615 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Daley, C. Emson, C. Guignabert, R. de Waal Malefyt, J. Louten, V. P. Kurup, C. Hogaboam, L. Taraseviciene-Stewart, N. F. Voelkel, M. Rabinovitch, et al. Pulmonary arterial remodeling induced by a Th2 immune response J. Exp. Med., February 18, 2008; 205(2): 361 - 372. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Hamidi, S. Prabhakar, and S. I. Said Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion Eur. Respir. J., January 1, 2008; 31(1): 135 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sawada, Y. Mitani, J. Maruyama, B. H. Jiang, Y. Ikeyama, F. A. Dida, H. Yamamoto, K. Imanaka-Yoshida, H. Shimpo, A. Mizoguchi, et al. A Nuclear Factor-{kappa}B Inhibitor Pyrrolidine Dithiocarbamate Ameliorates Pulmonary Hypertension in Rats Chest, October 1, 2007; 132(4): 1265 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Pak, A. Aldashev, D. Welsh, and A. Peacock The effects of hypoxia on the cells of the pulmonary vasculature Eur. Respir. J., August 1, 2007; 30(2): 364 - 372. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bonnet, G. Rochefort, G. Sutendra, S. L. Archer, A. Haromy, L. Webster, K. Hashimoto, S. N. Bonnet, and E. D. Michelakis The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted PNAS, July 3, 2007; 104(27): 11418 - 11423. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Tiev, J. Cabane, F. Aubourg, A. Kettaneh, M. Ziani, L. Mouthon, S. Duong-Quy, I. Fajac, L. Guillevin, and A. T. Dinh-Xuan Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Eur. Respir. J., July 1, 2007; 30(1): 26 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Taraseviciene-Stewart, M. R. Nicolls, D. Kraskauskas, R. Scerbavicius, N. Burns, C. Cool, K. Wood, J. E. Parr, S. A. Boackle, and N. F. Voelkel Absence of T Cells Confers Increased Pulmonary Arterial Hypertension and Vascular Remodeling Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1280 - 1289. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bonderman, N. Skoro-Sajer, J. Jakowitsch, C. Adlbrecht, D. Dunkler, S. Taghavi, W. Klepetko, M. Kneussl, and I. M. Lang Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension Circulation, April 24, 2007; 115(16): 2153 - 2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Said, S. A. Hamidi, K. G. Dickman, A. M. Szema, S. Lyubsky, R. Z. Lin, Y.-P. Jiang, J. J. Chen, J. A. Waschek, and S. Kort Moderate Pulmonary Arterial Hypertension in Male Mice Lacking the Vasoactive Intestinal Peptide Gene Circulation, March 13, 2007; 115(10): 1260 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, S. Mussot, M. Mazmanian, P. Herve, D. Emilie, G. Simonneau, and M. Humbert Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension Eur. Respir. J., March 1, 2007; 29(3): 462 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Levy, C. Maurey, D. S. Celermajer, P. R. Vouhe, C. Danel, D. Bonnet, and D. Israel-Biet Impaired Apoptosis of Pulmonary Endothelial Cells Is Associated With Intimal Proliferation and Irreversibility of Pulmonary Hypertension in Congenital Heart Disease J. Am. Coll. Cardiol., February 20, 2007; 49(7): 803 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gomberg-Maitland Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Eur. Respir. J., October 1, 2006; 28(4): 683 - 686. [Full Text] [PDF] |
||||
![]() |
V. V. McLaughlin and M. D. McGoon Pulmonary Arterial Hypertension Circulation, September 26, 2006; 114(13): 1417 - 1431. [Full Text] [PDF] |
||||
![]() |
P. Joppa, D. Petrasova, B. Stancak, and R. Tkacova Systemic Inflammation in Patients With COPD and Pulmonary Hypertension. Chest, August 1, 2006; 130(2): 326 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Witzenrath, B. Ahrens, S. M. Kube, A. C. Hocke, S. Rosseau, E. Hamelmann, N. Suttorp, and H. Schutte Allergic lung inflammation induces pulmonary vascular hyperresponsiveness Eur. Respir. J., August 1, 2006; 28(2): 370 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Sanchez, O. Sitbon, X. Jais, G. Simonneau, and M. Humbert Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest, July 1, 2006; 130(1): 182 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Hoeper, E. Mayer, G. Simonneau, and L. J. Rubin Chronic Thromboembolic Pulmonary Hypertension Circulation, April 25, 2006; 113(16): 2011 - 2020. [Full Text] [PDF] |
||||
![]() |
M. G. Frid, J. A. Brunetti, D. L. Burke, T. C. Carpenter, N. J. Davie, J. T. Reeves, M. T. Roedersheimer, N. van Rooijen, and K. R. Stenmark Hypoxia-Induced Pulmonary Vascular Remodeling Requires Recruitment of Circulating Mesenchymal Precursors of a Monocyte/Macrophage Lineage Am. J. Pathol., February 1, 2006; 168(2): 659 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mouthon, L. Guillevin, and M. Humbert Pulmonary arterial hypertension: an autoimmune disease? Eur. Respir. J., December 1, 2005; 26(6): 986 - 988. [Full Text] [PDF] |
||||
![]() |
M. R. Nicolls, L. Taraseviciene-Stewart, P. R. Rai, D. B. Badesch, and N. F. Voelkel Autoimmunity and pulmonary hypertension: a perspective Eur. Respir. J., December 1, 2005; 26(6): 1110 - 1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Montani, L. Achouh, A. G. Marcelin, J-P. Viard, O. Hermine, D. Canioni, O. Sitbon, G. Simonneau, and M. Humbert Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease Eur. Respir. J., November 1, 2005; 26(5): 969 - 972. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Kawut, E. M. Horn, K. K. Berekashvili, A. C. Widlitz, E. B. Rosenzweig, and R. J. Barst von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2355 - 2362. [Abstract] [Full Text] [PDF] |
||||
![]() |
M C Tamby, Y Chanseaud, M Humbert, J Fermanian, P Guilpain, P Garcia-de-la-Pena-Lefebvre, S Brunet, A Servettaz, B. Weill, G Simonneau, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension Thorax, September 1, 2005; 60(9): 765 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Song, J. E. Jones, H. Beppu, J. F. Keaney Jr, J. Loscalzo, and Y.-Y. Zhang Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice Circulation, July 26, 2005; 112(4): 553 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Stenmark, N. J. Davie, J. T. Reeves, and M. G. Frid Hypoxia, leukocytes, and the pulmonary circulation J Appl Physiol, February 1, 2005; 98(2): 715 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Huisman, S. A. Vreugdenhil, H. C. van Paassen, M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., January 20, 2005; 352(3): 308 - 309. [Full Text] [PDF] |
||||
![]() |
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF] |
||||
![]() |
T. M. Bull, C. D. Coldren, M. Moore, S. M. Sotto-Santiago, D. V. Pham, S. P. Nana-Sinkam, N. F. Voelkel, and M. W. Geraci Gene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 911 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436. [Full Text] [PDF] |
||||
![]() |
M. Humbert, N. W. Morrell, S. L. Archer, K. R. Stenmark, M. R. MacLean, I. M. Lang, B. W. Christman, E. K. Weir, O. Eickelberg, N. F. Voelkel, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 13S - 24S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.M. Kawut and H.I. Palevsky New answers raise new questions in pulmonary arterial hypertension Eur. Respir. J., June 1, 2004; 23(6): 799 - 801. [Full Text] [PDF] |
||||
![]() |
M. Humbert and G. Simonneau Sildenafil for Pulmonary Arterial Hypertension: Still Waiting for Evidence Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 6 - 7. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |